Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …

Background Ustekinumab, an interleukin (IL)‐12 and IL‐23 blocker, has emerged as a new
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …

Psoriasis is a chronic inflammatory, immune-mediated disease that affects 1% to 2% of the
world's population. Immunobiological medications are prescribed for certain patients with …

Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …

Background Ustekinumab is a monoclonal antibody that targets interleukin (IL)‐12/23 p40 to
treat psoriasis. The IL‐12 pathway is also important in regulating immunity to Mycobacterium …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

While the majority of patients with psoriasis will be treated with topical agents, a significant
number will still require escalation to systemic therapy. The choice of systemic therapy will …

Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …

Objectives: Ustekinumab is the most recently approved biologic for the treatment of
moderate-to-severe psoriasis. Real-world dosing patterns of ustekinumab are yet to be fully …

Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …